Ozempic Boom: Hims & Eli Lilly Lead Healthcare Bets

The healthcare sector is identified as a potential value play, driven by the 'Ozempic wave' of weight-loss treatments. Investors can gain exposure through diversified options like the Health Care Select Sector SPDR Fund (XLV), or via individual stocks offering distinct risk-reward profiles. Hims & Hers Health (HIMS) presents a higher-beta, subscription-based growth play with a 76.2% gross margin and institutional interest, while Eli Lilly (LLY) provides a stable, large-cap entry into the GLP-1 market with a lower beta of 0.44x and significant analyst-backed upside.

Analysis

The healthcare sector is presented as an underperforming area with potential for a valuation rebound, lagging the S&P 500 by approximately 26%. A primary catalyst identified is the burgeoning weight-loss drug market, exemplified by the 'Ozempic wave'. Investors can approach this theme through three distinct risk profiles. For diversified, lower-risk exposure, the Health Care Select Sector SPDR Fund (XLV) offers a play on a potential sector-wide rotation. For direct exposure, Eli Lilly (LLY) represents the stable, large-cap option with a $663 billion market capitalization and a low beta of 0.44. Wall Street sentiment for LLY is strong, with a 'Moderate Buy' consensus and a price target of $950.2, implying a 35.8% upside. In contrast, Hims & Hers Health (HIMS) is positioned as a higher-risk, high-growth opportunity characterized by a high beta of 2.10x. Its key strengths are a subscription-based business model that ensures recurring revenue and a remarkably high gross profit margin of 76.2%, which has attracted institutional investment like Nomura's $8 million stake. However, the investment case for HIMS is nuanced by a 'Reduce' rating from other analysts, indicating a more speculative profile compared to Eli Lilly.

Key Decisions for Investors

• Investors seeking broad exposure to a potential healthcare sector recovery with reduced single-stock risk should consider the Health Care Select Sector SPDR Fund (XLV), which currently trades at a significant performance gap to the broader market.
• For those prioritizing stability and established market leadership, Eli Lilly (LLY) offers a lower-volatility entry into the weight-loss drug theme, supported by a low 0.44 beta and a strong analyst consensus implying 35.8% upside.
• Aggressive growth investors with a higher risk tolerance could evaluate Hims & Hers (HIMS) for its unique subscription model and high gross margins, but must carefully weigh these positives against its high 2.10x beta and mixed analyst ratings.